CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a patent (U.S. Patent No. 11,033,569) protecting the composition of matter of F-star’s SB 11285, a second generation STING agonist.
News
Cambridge’s Mission Therapeutics is to receive a milestone payment of $20 million from Wall Street-quoted AbbVie as part of a neurodegenerative disease collaboration.
Mission is a drug discovery and development company focused on targeting the ubiquitin pathway; the partners are progressing selected deubiquitylating enzyme (DUB) targets into the next phase of research.
Cambridge, UK, 05 Aug 2021: o2h Ventures is delighted to announce an investment into BiVictriX Therapeutics, an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies using insights derived from frontline clinical experience.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc.
Cambridge, UK – 4 August 2021 – Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, today announced an exciting partnership with Ono Pharmaceutical Co., Ltd., one of Japan’s largest pharmaceutical companies and a global leader in the field of R&D-orientated drug discovery. The collaboration will leverage Healx’s innovative indication expansion technology to identify new disease indications with high unmet needs that could be treated by Ono’s proprietary assets.
London, UK, 04 August 2021: Closed Loop Medicine Ltd, a healthcare company focused on developing drug + digital combination products, the next generation of patient centric pharmaceutical products, reports positive regulatory clinical data for its insomnia drug, ahead of regulatory submission of its combination product CLM-IN01 for insomnia.
SOMERSET, N.J., August 3, 2021 – Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that, effective July 1, 2021, 97% of its electricity usage across its global network is being procured from renewable energy sources such as wind, solar, hydroelectric, and biomass.
2 August 2021, Cambridge, UK – Abcam plc (“Abcam”, “the Company” or “the Group”) (AIM LSE: ABC; Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that it has entered into a definitive agreement to acquire BioVision, Inc. (“BioVision”), a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. (“NKY”), for $340 million (the “Acquisition”).
Cambridge, UK, 3 August 2021 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today announced the closing of its oversubscribed Seed extension, bringing the total Seed round to $45 million. This extension of $34 million was led by Amsterdam-based investment firm Forbion together with global healthcare investors GV (formerly Google Ventures) and Northpond Ventures and supported by founding investors SV Health Investors, and Johnson & Johnson Innovation – JJDC, Inc..
LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced an agreement with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, granting Moderna an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus’ proprietary binders for up to four immuno-oncology targets.